Literature DB >> 28674470

Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea.

Fraidy Maltz, Brooke Fidler.   

Abstract

Eluxadoline (Viberzi) for the treatment of irritable bowel syndrome with diarrhea.

Entities:  

Year:  2017        PMID： 28674470      PMCID： PMC5481293     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  7 in total

Review 1.  Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.

Authors:  Brian E Lacy; Julie C Moreau
Journal:  J Am Assoc Nurse Pract       Date:  2016-07       Impact factor: 1.165

2.  American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.

Authors:  David S Weinberg; Walter Smalley; Joel J Heidelbaugh; Shahnaz Sultan
Journal:  Gastroenterology       Date:  2014-09-16       Impact factor: 22.682

3.  Eluxadoline for Irritable Bowel Syndrome with Diarrhea.

Authors:  Anthony J Lembo; Brian E Lacy; Marc J Zuckerman; Ron Schey; Leonard S Dove; David A Andrae; J Michael Davenport; Gail McIntyre; Rocio Lopez; Lisa Turner; Paul S Covington
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

4.  Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.

Authors:  Leonard S Dove; Anthony Lembo; Charles W Randall; Ronald Fogel; David Andrae; J Michael Davenport; Gail McIntyre; June S Almenoff; Paul S Covington
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

Review 5.  Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.

Authors:  Anastasia Rivkin; Sergey Rybalov
Journal:  Pharmacotherapy       Date:  2016-03-11       Impact factor: 4.705

6.  Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.

Authors:  Wakako Fujita; Ivone Gomes; Leonard S Dove; David Prohaska; Gail McIntyre; Lakshmi A Devi
Journal:  Biochem Pharmacol       Date:  2014-09-28       Impact factor: 5.858

7.  Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.

Authors:  J Michael Davenport; Paul Covington; Laura Bonifacio; Gail McIntyre; Jürgen Venitz
Journal:  J Clin Pharmacol       Date:  2015-01-14       Impact factor: 3.126
  7 in total
  1 in total

1.  Evaluation of Eluxadoline Effect on Cardiac Repolarization.

Authors:  Laura Bonifacio; Thomas L Hunt; Gail McIntyre; Leonard S Dove; Paul S Covington
Journal:  Clin Pharmacol Drug Dev       Date:  2018-04-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.